Announced details
Domestic Phase III clinical trial for pediatric patients with achondroplasia (ACH) aged 2–14
A cumulative total of 6 trial sites are now open for patient enrollment
Orphan drug designation
Ministry of Health, Labour and Welfare
Locations of the trial sites shown on a map (individual locations are not provided in the text)
No impact on full-year earnings for the fiscal year ending March 2027
The company does not address Contract Value / Offering price.
The Company's disclosure dated 18 March 2026, "Notice of Clinical Trial Application for the Domestic Phase III Clinical Trial of the Achondroplasia Treatment (umedaptanib pegol)"
| Item | Details |
|---|---|
| Names of Products / Services Covered | umedaptanib pegol（RBM-007） |
| Applicable area | Domestic Phase III clinical trial for pediatric patients with achondroplasia (ACH) aged 2–14 |
| Award/certification name | Orphan drug designation |
| Awarding / certifying body | Ministry of Health, Labour and Welfare |
| Location | Locations of the trial sites shown on a map (individual locations are not provided in the text) |
| Location scale | IRB approval obtained at a cumulative total of 6 medical institutions; expected to be expanded to a total of 16 sites |
| Usage history | A cumulative total of 6 trial sites are now open for patient enrollment |
| Impact on Business Performance | No impact on full-year earnings for the fiscal year ending March 2027 |
| Source | The Company's disclosure dated 18 March 2026, "Notice of Clinical Trial Application for the Domestic Phase III Clinical Trial of the Achondroplasia Treatment (umedaptanib pegol)" |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because achondroplasia is a rare disease with a limited patient population and the trial targets pediatric patients who are still growing, specialized expertise and careful management are required. The number of sites is expected to be expanded to a total of 16 to cover Japan nationwide.